SKYE SKYE BIOSCIENCE INC

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th.

The live webcast of the call can be accessed at the Skye website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website.

About Skye Bioscience

Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial () in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: . Connect with us on and .

CONTACTS

Investor Relations



(858) 410-0266

LifeSci Advisors, Mike Moyer



(617) 308-4306

Media Inquiries

LifeSci Communications, Michael Fitzhugh



(628) 234-3889



EN
07/05/2025

Underlying

SKYESKYE BIOSCIENCE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SKYE BIOSCIENCE INC

 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nima...

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide alone in preclinical diet-induced obesity modelIn vitro data reported from new preclinical study highlights superior potency of peripherally restricted CB1 inhibitor, nimacimab, versus monlunabant when tested under pathological levels of CB1 agonistsExpanded preclinical study data to be presented at ADA in June 2025Top-line data reado...

17h / 1m 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience to Announce 2025 First Quarter Financial Results on Ma...

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025 SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th. The live webcast of the call can be accessed at the Skye website, along with...

May 7, 2025 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience to Participate in May Investment and Medical Conferenc...

Skye Bioscience to Participate in May Investment and Medical Conferences SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences: Investment Conferences Citizens Life Sciences Conference (New York)Presentation, Thursday, May 8, 11:00 am ET + 1x1 meetings Craig-Hallum Institutional Investor Conference (Minneapolis)1x1 meetings, W...

April 29, 2025 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on April 23, 2025, the Board of Directors granted a non-qualified stock option award to purchase 19,000 shares of its common stock to one new non-executive employee under the Company’s Amended and Restated 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were gran...

April 26, 2025 1 EN
 PRESS RELEASE
Free
SKYE SKYE BIOSCIENCE...

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and T...

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity modelNew in vitro data demonstrates superior potency of nimacimab’s differentiated and favorable mechanism of inhibition versus monlunabant Nimacimab Phase 2a CBeyond™ top-line randomized data expected late Q3/early Q4 2025 SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye...

April 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch